DE602004014485D1 - Zusammensetzung und anwendungen von galectin-antagonisten - Google Patents

Zusammensetzung und anwendungen von galectin-antagonisten

Info

Publication number
DE602004014485D1
DE602004014485D1 DE602004014485T DE602004014485T DE602004014485D1 DE 602004014485 D1 DE602004014485 D1 DE 602004014485D1 DE 602004014485 T DE602004014485 T DE 602004014485T DE 602004014485 T DE602004014485 T DE 602004014485T DE 602004014485 D1 DE602004014485 D1 DE 602004014485D1
Authority
DE
Germany
Prior art keywords
applications
composition
galectin
antagonists
galectin antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004014485T
Other languages
English (en)
Inventor
Yan Chang
Vodek Sasak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prospect Therapeutics Inc
Original Assignee
Prospect Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/408,723 external-priority patent/US20040023925A1/en
Application filed by Prospect Therapeutics Inc filed Critical Prospect Therapeutics Inc
Publication of DE602004014485D1 publication Critical patent/DE602004014485D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004014485T 2003-04-07 2004-04-07 Zusammensetzung und anwendungen von galectin-antagonisten Expired - Lifetime DE602004014485D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46100603P 2003-04-07 2003-04-07
US10/408,723 US20040023925A1 (en) 2001-06-21 2003-04-07 Method for enhancing the effectiveness of therapies of hyperproliferative diseases
US47456203P 2003-05-30 2003-05-30
PCT/US2004/010675 WO2004091634A1 (en) 2003-04-07 2004-04-07 Composition and uses of galectin antagonists

Publications (1)

Publication Number Publication Date
DE602004014485D1 true DE602004014485D1 (de) 2008-07-31

Family

ID=33303850

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004014485T Expired - Lifetime DE602004014485D1 (de) 2003-04-07 2004-04-07 Zusammensetzung und anwendungen von galectin-antagonisten

Country Status (6)

Country Link
EP (2) EP1617849B1 (de)
JP (1) JP2006522163A (de)
AU (1) AU2004229399B2 (de)
CA (1) CA2521649C (de)
DE (1) DE602004014485D1 (de)
WO (1) WO2004091634A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128966B2 (en) 2004-03-26 2012-03-06 La Jolla Pharmaceutical Company Modified pectins, compositions and methods related thereto
ES2429041T3 (es) 2004-06-18 2013-11-12 Genentech, Inc. Combinación de un agente quimioterapéutico y un antagonista de un producto génico para tratar tumores
CA2665387A1 (en) * 2006-10-03 2008-04-10 University Of Southern California Grp78 as a predictor of responsiveness to therapeutic agents
JP2009221112A (ja) * 2008-03-13 2009-10-01 Unitec Foods Co Ltd 免疫機能調節組成物
CN102085214A (zh) * 2011-01-27 2011-06-08 范晓青 低分子柑橘果胶联和临床常用化疗药用于控制癌症和癌症转移扩散
DK2788761T3 (en) * 2011-12-08 2018-04-30 Eliaz Therapeutics Inc Reduction of galectin-3 levels by plasma apheresis
CN104245717B (zh) * 2011-12-28 2017-10-24 卡莱克汀医疗有限公司 用于治疗人类疾病的新型糖类药物的组合物
EP2858651B1 (de) 2012-06-06 2020-11-11 Galectin Therapeutics Inc. Galactorhamnogalacturonatzusammensetzungen zur behandlung von erkrankungen im zusammenhang mit erhöhter induzierbarer stickoxidsynthase
CN104812244B (zh) 2012-09-17 2018-10-30 卡莱克汀医疗有限公司 增强癌症治疗中特异性免疫疗法的方法
EP2934552A4 (de) 2012-12-20 2016-07-27 Ford Henry Health System Verfahren zur behandlung von diastolischer herzinsuffizienz durch galectin-3-hemmung
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
JP2017512205A (ja) * 2014-03-10 2017-05-18 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ 腎臓障害を治療するための組成物及び方法
BR112018000200A2 (pt) * 2015-07-10 2018-09-04 Dsm Ip Assets B.V. composições de comida e/ou ração para prevenir e tratar doenças inflamatórias
BR112019003946A2 (pt) * 2016-08-31 2019-05-21 Fujifilm Corporation agente antitumoral, reforçador do efeito antitumoral e kit antitumoral
EP3746123A4 (de) * 2018-02-01 2021-12-01 Memorial Sloan-Kettering Cancer Center Antikörper gegen galectin-3 und verfahren zur verwendung davon
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
WO2022240741A1 (en) 2021-05-12 2022-11-17 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
CN113999287B (zh) * 2021-12-02 2023-06-27 深圳湾实验室坪山生物医药研发转化中心 一种靶向半乳糖凝集素-10的多肽抑制剂及其制备方法和用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2448793A (en) 1943-08-17 1948-09-07 Askania Regulator Co Rectifier fed motor system
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5834442A (en) 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
KR19990087665A (ko) * 1996-03-15 1999-12-27 오미야 히사시 우론산의 가열-처리 산물, 이를 함유하는 식품, 음료 또는 약제
DE69931791T2 (de) * 1998-08-06 2007-05-24 Teijin Ltd. Pharmazeutische zusammensetzung die ein inhibierendes effekt auf die überproduktion und akkumulation der extrazellulären matrix hat
US6500807B1 (en) 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
US6274566B1 (en) 1999-02-23 2001-08-14 Econugenics, Inc. Methods for treating mammals with modified alginates and pectins
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
WO2000062076A1 (en) * 1999-04-13 2000-10-19 Hsu Daniel K Galectin expression is induced in cirrhotic liver and hepatocellular carcinoma
AU2001253255A1 (en) 2000-04-07 2001-10-23 Large Scale Biology Corporation Compositions and methods for inhibiting gene expression
SE0100172D0 (sv) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
WO2002100343A2 (en) 2001-06-08 2002-12-19 Mandalmed, Inc. N-terminally truncated galectin-3 and antibodies for treating cancer
US6680306B2 (en) 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20030004132A1 (en) 2001-06-22 2003-01-02 Yan Chang Method and material for treating immune diseases
US6890906B2 (en) 2001-11-21 2005-05-10 Glycogenesys, Inc. Method for controlling angiogenesis in animals

Also Published As

Publication number Publication date
JP2006522163A (ja) 2006-09-28
AU2004229399B2 (en) 2010-08-05
CA2521649A1 (en) 2004-10-28
EP1980257A1 (de) 2008-10-15
EP1617849A1 (de) 2006-01-25
CA2521649C (en) 2013-05-28
AU2004229399A1 (en) 2004-10-28
EP1617849B1 (de) 2008-06-18
WO2004091634A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
DE602004014485D1 (de) Zusammensetzung und anwendungen von galectin-antagonisten
ATE465712T1 (de) Ultrafeine zusammensetzungen von formoterol
DE602004005753D1 (de) Kombinationen von harzzusammensetzungen und verwendungsverfahren dafür
DE602004022192D1 (de) Strahlenhärtbare tintenzusammensetzungen und anwendungen dafür
DE602004020474D1 (de) Vegf-traps und deren therapeutische anwendungen
DE60207627D1 (de) Überzug und Überzugszusammensetzung
ATE350450T1 (de) Waschmittelzusammensetzungen und komponenten davon
DE60328206D1 (de) Scheibenwaschanlagendüse und scheibenwaschanlage
DE60227301D1 (de) Strukturen von anschlusselementen und anzuschliessende komponente
DE602005012267D1 (de) N von geräten
DE602004024731D1 (de) Tonerzusammensetzungen und Herstellungsverfahren
DE602005017635D1 (de) Harzzusammensetzung und formteil daraus
DE60112856D1 (de) Dämpfungsstruktur und anwendungen
FI20021660A0 (fi) Hiilihydraattien uusi käyttö ja koostumukset
DE60305611D1 (de) Tonzusammensetzung, Verfahren und Anwendungen damit
DE602004031607D1 (de) Propylenpolymerzusammensetzung und verwendung davon
DE60334292D1 (de) Ylenverbundemulsionszusammensetzung und verwendung davon
ATE442368T1 (de) 3-amino-2-arylpropylazaindole und anwendungen davon
DE60111430D1 (de) Hypochlorige säure zusammensetzung und ihre verwendungen
DE602004010426D1 (de) Mikrobizide zusammensetzungen und ihre verwendung
DE60322290D1 (de) Dielektrische Keramikzusammensetzung und Resonator
DE60224194D1 (de) Arzneizusammensetzungen enthaltend terbinafin und deren verwendung
DE50203297D1 (de) Mischungen aus wachsen und polymeradditiven
DE502004011575D1 (de) Verwendung von Dioldimerfettsäureestern
ATE499096T1 (de) Kombination von serotonin-wiederaufnahme-hemmern und agomelatin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition